• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.

作者信息

Emens L A, Adams S, Barrios C H, Diéras V, Iwata H, Loi S, Rugo H S, Schneeweiss A, Winer E P, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui S Y, Schmid P

机构信息

University of Pittsburgh Medical Center Hillman Cancer Center and Department of Medicine, Pittsburgh, USA.

Breast Cancer Center, and Department of Medicine, New York University Langone Health, Perlmutter Cancer Center, New York, USA.

出版信息

Ann Oncol. 2021 Dec;32(12):1650. doi: 10.1016/j.annonc.2021.10.002. Epub 2021 Nov 2.

DOI:10.1016/j.annonc.2021.10.002
PMID:34740469
Abstract
摘要

相似文献

1
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.《一线阿替利珠单抗联合白蛋白紫杉醇治疗不可切除、局部晚期或转移性三阴性乳腺癌：IMpassion130最终总生存分析》勘误：《肿瘤学年鉴》2021年；32卷：983 - 993页
Ann Oncol. 2021 Dec;32(12):1650. doi: 10.1016/j.annonc.2021.10.002. Epub 2021 Nov 2.
2
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993.
Ann Oncol. 2021 Oct;32(10):1308. doi: 10.1016/j.annonc.2021.07.013. Epub 2021 Aug 2.
3
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.阿替利珠单抗联合白蛋白紫杉醇作为不可切除的局部晚期或转移性三阴性乳腺癌（IMpassion130）的一线治疗：一项随机、双盲、安慰剂对照、III 期临床试验的更新疗效结果。
Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.
4
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
5
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.一线阿替利珠单抗联合白蛋白紫杉醇治疗不可切除、局部晚期或转移性三阴性乳腺癌：IMpassion130 最终总生存分析。
Ann Oncol. 2021 Aug;32(8):983-993. doi: 10.1016/j.annonc.2021.05.355. Epub 2021 Jul 1.
6
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.阿替利珠单抗（联合 Nab-紫杉醇）：晚期三阴性乳腺癌的治疗评价。
Drugs. 2020 Apr;80(6):601-607. doi: 10.1007/s40265-020-01295-y.
7
Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.阿替利珠单抗联合化疗对比化疗治疗晚期或转移性三阴性乳腺癌的成本效果分析。
Front Public Health. 2021 Oct 29;9:756899. doi: 10.3389/fpubh.2021.756899. eCollection 2021.
8
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
9
Atezolizumab in the treatment of metastatic triple-negative breast cancer.阿替利珠单抗治疗转移性三阴性乳腺癌。
Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.
10
First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.阿替利珠单抗联合白蛋白紫杉醇一线治疗晚期三阴性乳腺癌的成本效果分析。
Am J Clin Oncol. 2020 May;43(5):340-348. doi: 10.1097/COC.0000000000000671.

引用本文的文献

1
A multitier virtual screening of antagonists targeting PD-1/PD-L1 interface for the management of triple-negative breast cancer.针对三阴性乳腺癌的 PD-1/PD-L1 靶点的拮抗剂的多层次虚拟筛选。
Med Oncol. 2023 Sep 30;40(11):312. doi: 10.1007/s12032-023-02183-7.
2
Immunogenic Nanovesicle-Tandem-Augmented Chemoimmunotherapy via Efficient Cancer-Homing Delivery and Optimized Ordinal-Interval Regime.通过高效的癌症归巢递送和优化的序贯间隔方案实现免疫原性纳米囊泡串联增强化学免疫疗法。
Adv Sci (Weinh). 2022 Dec 1;10(1):e2205247. doi: 10.1002/advs.202205247.